- In June 2023, Lonza expanded its cell line development capabilities in Singapore, signaling a significant move to enhance its production and service offerings in the cell line development serum market, particularly in the growing Asia-Pacific region
- In May 2023, Thermo Fisher Scientific strengthened its position in the market by acquiring Gibco, a leading provider of cell culture media and reagents. This acquisition highlights the increasing consolidation within the industry and the growing demand for high-quality cell line development serums to support biopharmaceutical manufacturing
- In March 2023, Cytiva introduced a new serum-free cell culture medium designed for the production of monoclonal antibodies. This innovation reflects the ongoing shift toward serum-free solutions and the growing importance of specialized media in the production of biopharmaceuticals, indicating a trend toward more efficient and ethical manufacturing processes
